Comparison between2 Drugs in Lupus Nephritis

A

Al-Azhar University

Status and phase

Completed
Phase 4

Conditions

Lupus Nephritis

Treatments

Drug: mycophenolate
Drug: cyclo phosphamide

Study type

Interventional

Funder types

Other

Identifiers

NCT04424602
0000085

Details and patient eligibility

About

The aim of this work is to study the effect and side effects of the cyclophosphamide versus mycophenolate in lupus nephritis

Full description

Systemic lupus erythematosus (SLE), also known simply as lupus, is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. Symptoms vary between people and may be mild to severe. common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, feeling tired, and a red rash which is most commonly on the face. Often there are periods of illness, called flares, and periods of remission during which there are few symptoms.painless passage of blood or protein in the urine may often be the only presenting sign of kidney involvement. Acute or chronic renal impairment may develop with lupus nephritis, leading to acute or end-stage kidney failure. Because of early recognition and management of SLE, end-stage renal failure occurs in less than 5% of cases; except in the black population, where the risk is many times.Nephritis is the most severe manifestation of lupus. Between 1950s and 1970s, corticosteroids were used for the treatment of lupus nephritis (LN) ,and using of cyclophosphamide(CPM), improved the outcome dramatically with 5 years survival increasing from 17% to 80%.Subsequently, intravenous (iv) CPM became the standard of care in induction regimes; however, ivCPM was associated with complications such as bladder toxicity, gonadal problems, and infections. To reduce the toxicity, low-dose of 500mg iv(CPM) every two weeks for six months showed equivalent efficacy and less side effect. Mycophenolatemofetil(MMF) is widely used in solid organ transplantation and it reduces the rate of acute rejection following renal transplantation. It has also been used to treat patients with other immune-mediated disorders such as immunoglobulin A nephropathy, small-vessel vasculitides and psoriasis . Lupus nephritisis inflammation of the kidney that is caused by systemic lupus erythematous (SLE). Lupus nephritis happens when lupus involves the kidneys.its symptoms, though, are not always dramatic. for many, the first noticeable symptom is swelling of the legs, ankles and feet. less often, there can be swelling in the face or hands.

Enrollment

40 patients

Sex

Female

Ages

20 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. All patients have systemic lupus erythromatosis with lupus nephritis either newly diagnosed or with history of SLE with lupus nephrits
  2. All stage of lupus nephritis except stage(i,v,vi)
  3. patients who accepted to participate in the study.

Exclusion criteria

  1. Patient with acute inflammatory process such as(rheumatoid arthritis or other rhumatoligical diseases).
  2. Patients who are taking other immunosuppressive therapy.
  3. Patients with malignancies.
  4. Patients with HCV, HBV or HIV infection.
  5. Patients with lupus nephritis sage(i,v,vi).

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

40 participants in 2 patient groups

cyclophosphamide
Experimental group
Description:
participants will receive intra venous cyclophosphamide 500mg once every two weeks for 6months.
Treatment:
Drug: cyclo phosphamide
mycophenolate
Active Comparator group
Description:
participants will receive oral mycophenolat 2 to 3mg/kg for 6 months.
Treatment:
Drug: mycophenolate

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems